Skip to main content

Table 3 Relationship between the clinicopathologic characteristics of AEG and the expression of TAZ or β-catenin

From: Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction

Clinicopathologic characteristics TAZ P β-catenin (nuclear) P β-catenin (membranous) P TAZ & β-catenin (nuclear) P TAZ & β-catenin (membranous) P
  Negative Positive   Negative Positive   Normal Abnormal   Others Positive   Others Positive  
Gender
Male 64 46 0.593 52 58 0.431 45 65 0.312 79 31 0.99 64 46 0.842
Female 16 9 14 11 13 12 18 7 14 11
Age
<60 years old 26 22 0.371 13 35 0.001 21 27 0.891 31 17 0.163 22 26 0.037
≥60 years old 54 33 53 34 37 50 66 21 56 31
Invasion of serosa
Positive 21 38 0.001 21 38 0.006 18 41 0.010 31 28 0.001 25 34 0.001
Negative 59 17 45 31 40 36 66 10 53 23
lymphatic metastasis
Positive 34 42 0.001 30 46 0.013 27 49 0.048 43 33 0.001 37 39 0.015
Negative 46 13 36 23 31 28 54 5 41 18
Differentiation
Well-differentiated 51 22 0.007 43 30 0.012 47 26 0.001 59 14 0.012 57 16 0.001
Poorly differentiated 29 33 23 39 11 51 38 24 21 41
TNM stage
Stage 0 I II 55 24 0.004 43 36 0.126 39 40 0.074 65 14 0.001 65 32 0.001
Stage III IV 25 31   23 33   19 37   32 24   14 24